abstract |
The present invention relates to: an antibody-drug conjugate in which a modified antibody, containing a motif of a specific structure at an end of the antibody, is coupled to a drug through a linker; and a composition containing the same and, specifically, to: a modified antibody-drug conjugate (mADC) comprising a modified antibody coupled to the C-terminus of heavy chain or light chain so as to have a remarkably increased drug conjugation yield; and a composition containing the same. |